391 related articles for article (PubMed ID: 26052390)
1. Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease.
Souza-Mello V
World J Hepatol; 2015 May; 7(8):1012-9. PubMed ID: 26052390
[TBL] [Abstract][Full Text] [Related]
2. Anti-obesogenic effects of WY14643 (PPAR-alpha agonist): Hepatic mitochondrial enhancement and suppressed lipogenic pathway in diet-induced obese mice.
Veiga FMS; Graus-Nunes F; Rachid TL; Barreto AB; Mandarim-de-Lacerda CA; Souza-Mello V
Biochimie; 2017 Sep; 140():106-116. PubMed ID: 28711683
[TBL] [Abstract][Full Text] [Related]
3. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A
Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255
[TBL] [Abstract][Full Text] [Related]
4. Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones.
Geisler CE; Renquist BJ
J Endocrinol; 2017 Jul; 234(1):R1-R21. PubMed ID: 28428362
[TBL] [Abstract][Full Text] [Related]
5. A PPAR Pan Agonist, MHY2013 Alleviates Age-Related Hepatic Lipid Accumulation by Promoting Fatty Acid Oxidation and Suppressing Inflammation.
An HJ; Lee B; Kim SM; Kim DH; Chung KW; Ha SG; Park KC; Park YJ; Kim SJ; Yun HY; Chun P; Yu BP; Moon HR; Chung HY
Biol Pharm Bull; 2018; 41(1):29-35. PubMed ID: 29311481
[TBL] [Abstract][Full Text] [Related]
6. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
Qiu YY; Zhang J; Zeng FY; Zhu YZ
Pharmacol Res; 2023 Jun; 192():106786. PubMed ID: 37146924
[TBL] [Abstract][Full Text] [Related]
7. Activation of the Peroxisome Proliferator-Activated Receptors (PPAR-
AlNafea HM; Korish AA
PPAR Res; 2021; 2021():5558731. PubMed ID: 34306045
[TBL] [Abstract][Full Text] [Related]
8. Chronic treatment with the modified Longdan Xiegan Tang attenuates olanzapine-induced fatty liver in rats by regulating hepatic de novo lipogenesis and fatty acid beta-oxidation-associated gene expression mediated by SREBP-1c, PPAR-alpha and AMPK-alpha.
Ren L; Sun D; Zhou X; Yang Y; Huang X; Li Y; Wang C; Li Y
J Ethnopharmacol; 2019 Mar; 232():176-187. PubMed ID: 30590197
[TBL] [Abstract][Full Text] [Related]
9. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
[TBL] [Abstract][Full Text] [Related]
10. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease.
Choudhary NS; Kumar N; Duseja A
J Clin Exp Hepatol; 2019; 9(6):731-739. PubMed ID: 31889755
[TBL] [Abstract][Full Text] [Related]
12. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
13. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
14. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells.
Hellemans K; Michalik L; Dittie A; Knorr A; Rombouts K; De Jong J; Heirman C; Quartier E; Schuit F; Wahli W; Geerts A
Gastroenterology; 2003 Jan; 124(1):184-201. PubMed ID: 12512042
[TBL] [Abstract][Full Text] [Related]
16. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
[TBL] [Abstract][Full Text] [Related]
17. Mouse trefoil factor 3 ameliorated high-fat-diet-induced hepatic steatosis via increasing peroxisome proliferator-activated receptor-α-mediated fatty acid oxidation.
Wu X; Zheng H; Yang R; Luan X; Zhang L; Jin Q; Jin Y; Xue J
Am J Physiol Endocrinol Metab; 2019 Sep; 317(3):E436-E445. PubMed ID: 31211621
[TBL] [Abstract][Full Text] [Related]
18. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation.
Schoonjans K; Staels B; Auwerx J
Biochim Biophys Acta; 1996 Jul; 1302(2):93-109. PubMed ID: 8695669
[TBL] [Abstract][Full Text] [Related]
19. PPAR: a mediator of peroxisome proliferator action.
Green S
Mutat Res; 1995 Dec; 333(1-2):101-9. PubMed ID: 8538617
[TBL] [Abstract][Full Text] [Related]
20. Singular effects of PPAR agonists on nonalcoholic fatty liver disease of diet-induced obese mice.
Barbosa-da-Silva S; Souza-Mello V; Magliano DC; Marinho Tde S; Aguila MB; Mandarim-de-Lacerda CA
Life Sci; 2015 Apr; 127():73-81. PubMed ID: 25748419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
